Abstract:Introduction: Carbapenem resistant Acinetobacter baumannii (CRAB) has emerged worldwide, as an alarming pathogen causing healthcare associated infections. It mostly involves patients with impaired host defenses, and those with debilitating illnesses. CRAB is declared as the top priority pathogen by the World Health Organization for the development of new drugs. Aims & Objectives: i) To determine the frequency of isolation of Acinetobacter baumannii from clinical samples ii) To detect carbapenem resistance in clinical isolates of A. baumannii iii) To understand the risks factors associated with acquisition of CRAB. Methods: The clinical samples were subjected to culture i) by conventional methods as per standard bacteriological techniques, and ii) by an automated BACTEC System (BD). The isolates grown onto culture media were identied i) by conventional methods, and ii) by an automated VITEK 2 system (Biomerieux). Antibiotic susceptibility testing was performed i) by the Kirby Bauer disc diffusion method as per CLSI guidelines, and ii) by VITEK 2 system. All the meropenem resistant isolates of A. baumanni were subjected to i) Modied Hodge Test (MHT) for the production of carbapenemase, and ii) Combined Disk Test (CDT), using imipenem and EDTA, for the production of metallo-betalactamase. Results: The frequency of isolation of Acinetobacter species was found to be 5.7%, of which the predominant was A. baumanni (89.3%). Among the isolates of A. baumannii, the frequency of meropenem resistance was found to be 72.1%. Meropenem resistant isolates of A. baumannii were most commonly obtained from patients admitted in intensive care units (86.3%). CRAB isolates were most frequently recovered from endotracheal aspirate (34.2%), followed by pus (29.8%), blood (20.7%), sputum (8.2%) and urine (5.6%) The most common risk factor associated with CRAB was mechanical ventilation (35.5%), followed by previous antibiotic usage (28.5%), indwelling catheters (11.1%), prolonged hospitalization (9.7%), chronic obstructive pulmonary disease (8.1%) and diabetes (5.7%). Out of 922 CRAB isolates, 757 (82.1%) were carbapenemase producers. Among the CRAB isolates, 31.9% were found to be only MHT positive, 26.7% were only CDT positive, 23.5% were both MHT and CDT positive, and the remaining 17.9% were both MHT and CDT negative. Conclusion: Emergence of infections with CRAB emphasizes the need for continuous surveillance, judicious use of antibiotics, and implementation of aggressive infection control strategies.

Metabolomics Method in Understanding and Sensitizing Carbapenem-Resistant <i>Acinetobacter baumannii</i> to Meropenem

Metabolomics Method in Understanding and Sensitizing Carbapenem-Resistant Acinetobacter baumannii to Meropenem

Metabolic Analyses Revealed Time-Dependent Synergistic Killing by Colistin and Aztreonam Combination Against Multidrug-Resistant Acinetobacter Baumannii

The Relationship Between AdeB Efflux System of Multidrug Resistant Acinetobacter Baumannii and Carbapenem Resistance

High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii

Acinetobacter Baumannii: Clinical Analysis and Combined Susceptibility Effects in Vitro

Synergistic Antibacterial Activity of Combined Antimicrobials and the Clinical Outcome of Patients With Carbapenemase-Producing Acinetobacter baumannii Infection

Genomic Insights into and In Vitro Evaluation of Antimicrobial Combination Therapies for Carbapenem-Resistant Acinetobacter baumannii

A Preliminary Exploration on the Mechanism of the Carbapenem-Resistance Transformation of Serratia Marcescens in Vivo

Discovery of novel BfmR inhibitors restoring carbapenem susceptibility against carbapenem-resistant Acinetobacter baumannii by structure-based virtual screening and biological evaluation

CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII - A CHALLENGING THREAT IN HEALTHCARE

Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii

High level non-carbapenemase carbapenem resistance by overlaying mutations of mexR, oprD, and ftsI in Pseudomonas aeruginosa

Epidemiology and resistance mechanism study of carbapenem-resistant Acinetobacter ba umannii

Transcriptomic investigations of polymyxins and colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii

Combatting Planktonic and Biofilm Populations of Carbapenem-Resistant Acinetobacter baumannii with Polymyxin-Based Combinations

Study on the mechanism of carbapenem resistance in Acinetobacter baumannii

Resistant mechanisms and molecular epidemiological characteristics of carbapenem-resistant Acinetobacter baumannii

Verification and Application of a Modified Carbapenem Inactivation Method (mcim) on Pseudomonas Aeruginosa: a Potential Screening Methodology on Carbapenemases Phenotype in Bacillus Cereus

Antimicrobial peptide DvAMP combats carbapenem-resistant Acinetobacter baumannii infection

Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections